First in Human Study of AZD9592 in solid tumors

Trial Identifier: D9350C00001
Sponsor: AstraZeneca
Start Date: December 2022
Primary Completion Date: October 2027
Study Completion Date: October 2027
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Kogarah, AU, 2217
AU Melbourne, AU, 3000
CA, AB Edmonton, AB, CA, T6G 1Z2
CA, ON Toronto, ON, CA, M5G 1X6
CN Beijing, CN, 100142
CN Chongqing, CN, 400030
CN Guangzhou, CN, 510100
CN Harbin, CN, 150049
CN Wuhan, CN, 430022
ES Barcelona, ES, 8035
ES Madrid, ES, 28040
ES Sevilla, ES, 41013
FR Marseille, FR, 13385
FR Rennes, FR, 35000
FR Villejuif Cedex, FR, 94805
IT Milano, IT, 20162
IT Orbassano, IT, 10043
IT Rozzano, IT, 20089
IT Verona, IT, 37134
JP Chuo-ku, JP, 104-0045
JP Kashiwa, JP, 277-8577
JP Koto-ku, JP, 135-8550
JP Osaka-shi, JP, 541-8567
KR Seoul, KR, 03722
KR Seoul, KR, 06351
KR Seoul, KR, 05505
KR Seoul, KR, 03080
MY Kuala Lumpur, MY, 59100
MY Kuching, MY, 93586
TW Taichung, TW, 40705
TW Taipei, TW, 10002
TW Taipei, TW, 11217
TW Taoyuan, TW, 333
US, CA Duarte, CA, US, 91010
US, CT North Haven, CT, US, 06473
US, DC Washington, DC, US, 20016
US, IL Chicago, IL, US, 60637
US, MA Milford, MA, US, 01757
US, MD Baltimore, MD, US, 21231
US, MD Baltimore, MD, US, 21224
US, NY Mineola, NY, US, 11501
US, NY New York, NY, US, 10021
US, NY New York, NY, US, 10016
US, NY New York, NY, US, 10029
US, PA Philadelphia, PA, US, 19104
US, RI Providence, RI, US, 02903
US, TX Houston, TX, US, 77030
US, VA Fairfax, VA, US, 22031